David Hui1, Omar Shamieh2, Carlos Eduardo Paiva3, Pedro Emilio Perez-Cruz4, Jung Hye Kwon5, Mary Ann Muckaden6, Minjeong Park7, Sriram Yennu1, Jung Hun Kang8, Eduardo Bruera1. 1. Department of Palliative Care and Rehabilitation Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Palliative Care, King Hussein Cancer Center, Amman, Jordan. 3. Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil. 4. Department of Internal Medicine, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile. 5. Department of Medical Oncology, Kangdong Sacred Heart Hospital, Seoul, Republic of Korea. 6. Department of Palliative Care, Tata Memorial Center, Mumbai, India. 7. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Division of Hematology/Oncology, Department of Internal Medicine, Gyeongsang University College of Medicine, Gyeongsang, Republic of Korea.
Abstract
BACKGROUND: The Edmonton Symptom Assessment Scale (ESAS) is widely used for symptom assessment in clinical and research settings. A sensitivity-specificity approach was used to identify the minimal clinically important difference (MCID) for improvement and deterioration for each of the 10 ESAS symptoms. METHODS: This multicenter, prospective, longitudinal study enrolled patients with advanced cancer. ESAS was measured at the first clinic visit and at a second visit 3 weeks later. For each symptom, the Patient's Global Impression ("better," "about the same," or "worse") was assessed at the second visit as the external criterion, and the MCID was determined on the basis of the optimal cutoff in the receiver operating characteristic (ROC) curve. A sensitivity analysis was conducted through the estimation of MCIDs with other approaches. RESULTS: For the 796 participants, the median duration between the 2 study visits was 21 days (interquartile range, 18-28 days). The area under the ROC curve varied from 0.70 to 0.87, and this suggested good responsiveness. For all 10 symptoms, the optimal cutoff was ≥1 point for improvement and ≤-1 point for deterioration, with sensitivities of 59% to 85% and specificities of 69% to 85%. With other approaches, the MCIDs varied from 0.8 to 2.2 for improvement and from -0.8 to -2.3 for deterioration in the within-patient analysis, from 1.2 to 1.6 with the one-half standard deviation approach, and from 1.3 to 1.7 with the standard error of measurement approach. CONCLUSIONS: ESAS was responsive to change. The optimal cutoffs were ≥1 point for improvement and ≤-1 point for deterioration for each of the 10 symptoms. Our findings have implications for sample size calculations and response determination.
BACKGROUND: The Edmonton Symptom Assessment Scale (ESAS) is widely used for symptom assessment in clinical and research settings. A sensitivity-specificity approach was used to identify the minimal clinically important difference (MCID) for improvement and deterioration for each of the 10 ESAS symptoms. METHODS: This multicenter, prospective, longitudinal study enrolled patients with advanced cancer. ESAS was measured at the first clinic visit and at a second visit 3 weeks later. For each symptom, the Patient's Global Impression ("better," "about the same," or "worse") was assessed at the second visit as the external criterion, and the MCID was determined on the basis of the optimal cutoff in the receiver operating characteristic (ROC) curve. A sensitivity analysis was conducted through the estimation of MCIDs with other approaches. RESULTS: For the 796 participants, the median duration between the 2 study visits was 21 days (interquartile range, 18-28 days). The area under the ROC curve varied from 0.70 to 0.87, and this suggested good responsiveness. For all 10 symptoms, the optimal cutoff was ≥1 point for improvement and ≤-1 point for deterioration, with sensitivities of 59% to 85% and specificities of 69% to 85%. With other approaches, the MCIDs varied from 0.8 to 2.2 for improvement and from -0.8 to -2.3 for deterioration in the within-patient analysis, from 1.2 to 1.6 with the one-half standard deviation approach, and from 1.3 to 1.7 with the standard error of measurement approach. CONCLUSIONS:ESAS was responsive to change. The optimal cutoffs were ≥1 point for improvement and ≤-1 point for deterioration for each of the 10 symptoms. Our findings have implications for sample size calculations and response determination.
Authors: R D Nipp; A El-Jawahri; M Ruddy; C Fuh; B Temel; S M D'Arpino; B J Cashavelly; V A Jackson; D P Ryan; E P Hochberg; J A Greer; J S Temel Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Lauren R Pollack; Nathan E Goldstein; Wendy C Gonzalez; Craig D Blinderman; Mathew S Maurer; David J Lederer; Matthew R Baldwin Journal: J Am Geriatr Soc Date: 2017-03-06 Impact factor: 5.562
Authors: Gabriel Lopez; Wenli Liu; Kevin Madden; Bryan Fellman; Yisheng Li; Eduardo Bruera Journal: Support Care Cancer Date: 2017-10-29 Impact factor: 3.603
Authors: Gabriel Lopez; Wenli Liu; Kathrin Milbury; Amy Spelman; Qi Wei; Eduardo Bruera; Lorenzo Cohen Journal: Support Care Cancer Date: 2017-06-28 Impact factor: 3.603
Authors: David Hui; Minjeong Park; Omar Shamieh; Carlos Eduardo Paiva; Pedro Emilio Perez-Cruz; Mary Ann Muckaden; Eduardo Bruera Journal: Cancer Date: 2016-03-11 Impact factor: 6.860